Growth Metrics

Gilead Sciences (GILD) Cash from Operations (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -23.53%
Dec 31, 2025 -19.01%
Sep 30, 2025 396.74%
Jun 30, 2025 -52.93%
Mar 31, 2025 -40.94%
Dec 31, 2024 -30.96%
Sep 30, 2024 225.21%
Jun 30, 2024 -40.29%
Mar 31, 2024 2.31%
Dec 31, 2023 23.59%
Sep 30, 2023 -24.94%
Jun 30, 2023 34.06%
Mar 31, 2023 -32.06%
Dec 31, 2022 -10.34%
Sep 30, 2022 58.88%
Jun 30, 2022 -2.07%
Mar 31, 2022 -42.59%
Dec 31, 2021 -1.48%
Sep 30, 2021 40.46%
Jun 30, 2021 -11.26%
Mar 31, 2021 36.22%
Dec 31, 2020 -14.84%
Sep 30, 2020 -12.31%
Jun 30, 2020 78.69%
Mar 31, 2020 -44.34%
Dec 31, 2019 -2.46%
Sep 30, 2019 12.94%
Jun 30, 2019 48.51%
Mar 31, 2019 -32.75%
Dec 31, 2018 6.01%
Sep 30, 2018 40.62%
Jun 30, 2018 -30.70%
Mar 31, 2018 -17.54%
Dec 31, 2017 2.19%
Sep 30, 2017 -23.60%
Jun 30, 2017 20.55%
Mar 31, 2017 -17.35%
Dec 31, 2016 -19.44%
Sep 30, 2016 -11.88%
Jun 30, 2016 20.70%
Mar 31, 2016 -28.73%
Dec 31, 2015 41.48%
Sep 30, 2015 -27.61%
Jun 30, 2015 -0.75%
Mar 31, 2015 88.71%
Dec 31, 2014 -25.30%
Sep 30, 2014 -3.37%
Jun 30, 2014 166.90%
Mar 31, 2014 115.74%
Dec 31, 2013 -3.49%
Sep 30, 2013 -20.98%
Jun 30, 2013 41.79%
Mar 31, 2013 -4.80%
Dec 31, 2012 -5.28%
Sep 30, 2012 -42.25%
Jun 30, 2012 184.93%
Mar 31, 2012 -53.69%
Dec 31, 2011 9.03%
Sep 30, 2011 -4.89%
Jun 30, 2011 14.96%
Mar 31, 2011 13.20%
Dec 31, 2010 -1.97%
Sep 30, 2010 5.77%
Jun 30, 2010 4.25%
Mar 31, 2010 -29.80%
Dec 31, 2009 11.01%
Sep 30, 2009 38.15%
Jun 30, 2009 -2.87%